scholarly journals Determination of Transcriptional Changes Induced by an Ovarian Cancer Targeting Peptide

2018 ◽  
Vol 32 (S1) ◽  
Author(s):  
Lindsey Weintraub ◽  
James Rudy ◽  
Susan Hum‐Musser ◽  
Richard Musser ◽  
Mette Soendergaard
Keyword(s):  
Ovarian Cancer ◽  
Cancer Targeting ◽  
Transcriptional Changes ◽  
Targeting Peptide

scholarly journals An SPRi Biosensor for Determination of the Ovarian Cancer Marker HE4 in Human Plasma

Sensors ◽  
2021 ◽  
Vol 21 (10) ◽  
pp. 3567
Author(s):  
Beata Szymanska ◽  
Zenon Lukaszewski ◽  
Beata Zelazowska-Rutkowska ◽  
Kinga Hermanowicz-Szamatowicz ◽  
Ewa Gorodkiewicz
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Tumor Resection ◽  
Analytical Signal ◽  
Cancer Marker ◽  
Human Epididymis Protein 4 ◽  
Pearson Coefficient ◽  
Rabbit Polyclonal Antibody ◽  
Good Agreement

Human epididymis protein 4 (HE4) is an ovarian cancer marker. Various cut-off values of the marker in blood are recommended, depending on the method used for its determination. An alternative biosensor for HE4 determination in blood plasma has been developed. It consists of rabbit polyclonal antibody against HE4, covalently attached to a gold chip via cysteamine linker. The biosensor is used with the non-fluidic array SPRi technique. The linear range of the analytical signal response was found to be 2–120 pM, and the biosensor can be used for the determination of the HE4 marker in the plasma of both healthy subjects and ovarian cancer patients after suitable dilution with a PBS buffer. Precision (6–10%) and recovery (101.8–103.5%) were found to be acceptable, and the LOD was equal to 2 pM. The biosensor was validated by the parallel determination of a series of plasma samples from ovarian cancer patients using the Elecsys HE4 test and the developed biosensor, with a good agreement of the results (a Pearson coefficient of 0.989). An example of the diagnostic application of the developed biosensor is given—the influence of ovarian tumor resection on the level of HE4 in blood serum.

Mussel-Derived, Cancer-Targeting Peptide as pH-Sensitive Prodrug Nanocarrier

2019 ◽  
Vol 11 (27) ◽  
pp. 23948-23956 ◽  
Author(s):  
Yue Ma ◽  
Peiyan He ◽  
Xiaohua Tian ◽  
Guanglei Liu ◽  
Xiaowei Zeng ◽  
...  
Keyword(s):  
Ph Sensitive ◽  
Cancer Targeting ◽  
Targeting Peptide

Determination of HE4-mediated roles in tumor immune system modulation in Epithelial Ovarian Cancer (EOC)

2015 ◽  
Vol 139 (3) ◽  
pp. 591
Author(s):  
Anze Urh ◽  
Nicole Romano ◽  
KyuKwang Kim ◽  
Jennifer Ribeiro ◽  
Christina Raker ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune System ◽  
Epithelial Ovarian Cancer ◽  
Immune System Modulation

scholarly journals Predictive factors of endometriosis progression into ovarian cancer

2022 ◽  
Vol 15 (1) ◽  
Author(s):  
Ján Varga ◽  
Alžbeta Reviczká ◽  
Hedviga Háková ◽  
Peter Švajdler ◽  
Miroslava Rabajdová ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Predictive Factors ◽  
Control Group ◽  
Histopathological Analysis ◽  
Genes Expression ◽  
Patients At Risk ◽  
Conventional Cytogenetics ◽  
Normal Cytogenetics ◽  
Atypical Endometriosis

Abstract Background In recent years, the endometriosis has overcome a noteworthy renaissance in the recognition of its potential. In certain patients, a demonstrable malignant progression of ectopic foci leading to development of ovarian cancer is seen. The knowledge of endometriosis overthrow background into endometriosis associated ovarian cancer is of paramount importance for selection of patients at risk. The goal of the presented study was to review a malignant potential of the endometriosis and to specify predictive factors of endometriosis progression into ovarian cancer. Altogether 189 patients were included in the study. Conventional cytogenetics as well as measurement of transcriptional activity of CTNNB1 (β-catenin) and HIF1A (HIF1-α) genes were prospectively studied in 60 endometriosis patients and 50 control group patients. The retrospective histopathological analysis was performed in 19 endometriosis associated ovarian cancer patients and 60 patients with histologically confirmed endometriosis. Results Five endometriosis patients showed a deviation from normal cytogenetics finding without affecting of their phenotype. In 6 cases of endometriosis associated ovarian cancer ectopic endometrium was not confirmed. The remaining 13 cases demonstrated either benign or atypical endometriosis or even structures of borderline carcinoma. Atypical endometriosis was histologically confirmed in 20% of 60 endometriosis patients. Determination of gene expression (CTNNB1, HIF1A) formed two subgroups. Transcriptionally incipient endometriosis subgroup with insignificant genes expression compared to control group. In transcriptionally evident endometriosis subgroup were genes expressions significantly higher compared to control group (p < 0.01) as well as transcriptionally incipient endometriosis subgroup (p < 0.05). Conclusions Significant structural abnormalities of chromosomes are not included in genetic rigging of endometriosis patients. Atypical endometriosis represents a histopathologically detectable intermediate of endometriosis progression. Determination of genes expression CTNNB1 and HIF1A helps to allocate risk patients with endometriosis where more precise management is needed.

scholarly journals High Resolution Based Quantitative Determination of Methylation Status of CDH1 and VIM Gene in Epithelial Ovarian Cancer

2019 ◽  
Vol 20 (10) ◽  
pp. 2923-2928
Author(s):  
Gaurav Kr Thakur ◽  
Tusha Sharma ◽  
T Krishna Latha ◽  
B D Banerjee ◽  
Harendra Kr Shah ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
High Resolution ◽  
Quantitative Determination ◽  
Epithelial Ovarian Cancer ◽  
Methylation Status

Determination of Both TP53 Mutation Status and the Amount of p53 Protein Has Limited Diagnostic Importance for Patients with Ovarian Cancer

2022 ◽  
Vol 29 ◽  
Author(s):  
Sebastian M. Klein ◽  
Maria Bozko ◽  
Astrid Toennießen ◽  
Nisar P. Malek ◽  
Przemyslaw Bozko
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Tp53 Mutation ◽  
P53 Protein ◽  
Mutation Status ◽  
Tumor Tissues ◽  
Tp53 Status ◽  
Diagnostic Importance

Background: Ovarian cancer is one of the most aggressive types of gynecologic cancers. Many patients have a relapse within two years after diagnosis and subsequent therapy. Among different genetic changes generally believed to be important for the development of cancer, TP53 is the most common mutation in the case of ovarian tumors. Objective: Our work aims to compare the outcomes of different comparisons based on the overall survival of ovarian cancer patients, determination of TP53 status, and amount of p53 protein in tumor tissues. Methods: We analyzed and compared a collective of 436 ovarian patient’s data. Extracted data include TP53 mutation status, p53 protein level, and information on the overall survival. Values for p53 protein level in dependence of TP53 mutation status were compared using the Independent-Samples t-Test. Survival analyses were displayed by Kaplan-Meier plots, using the log-rank test to check for statistical significance. Results: We have not found any statistically significant correlations between determination of TP53 status, amount of p53 protein in tumor tissues, and overall survival of ovarian cancer patients. Conclusion: In ovarian tumors both determination of TP53 status as well as p53 protein amount has only limited diagnostic importance.

New Germinal Mutation of BRCA1 gene (c.829_832delAATA) in a Polish Patient with Breast/Ovarian Cancer

2020 ◽  
Author(s):  
Malgorzata Ostrowska ◽  
Justyna Podlodowska ◽  
Jadwiga Sierocinska-Sawa ◽  
Jacek Wojcierowski
Keyword(s):  
Ovarian Cancer ◽  
Brca1 Gene ◽  
Adenosine Diphosphate ◽  
Molecular Techniques ◽  
Polish Population ◽  
Single Nucleotide Variants ◽  
Familial Predisposition ◽  
Pathogenic Variants ◽  
Therapeutic Benefits

Abstract Background: Determination of the BRCA1/BRCA2 mutation status in patients with breast and/or ovarian cancer is commonly performed using various molecular techniques. The use only of targeted PCR-based tests may not be sufficient, as not all possible variants are investigated. Quick and effective diagnosis in order to apply the appropriate treatment is extremely important. In the following study, we used next generation sequencing (NGS) techniques to identify novel pathogenic variants in BRCA1 and BRCA2. Methods: In this study, material (blood and FFPE) collected from a 67-year-old patient with ovarian cancer was used. The presence of hereditary mutations characteristic for the Polish population was examined using Sanger sequencing. BRCA1 and BRCA2 gene exons were amplified using the Devyser BRCA kit and sequenced on the Miniseq.Results: No germline mutations characteristic for the Polish population were detected. However,12 single nucleotide variants and 2 indels were identified. We found a new deleterious mutation of gene BRCA1 (c.829_832delAATA). To our knowledge, this mutation has not been reported yet in the Polish population and others. Conclusions: The use of the NGS technique increases the possibilities of detecting mutational changes in patients with ovarian and/or breast cancer. The frequency of somatic mutations in ovarian tumors is low (3% - 9%) but their detection may have therapeutic benefits due to the use of poly(adenosine diphosphate)-ribose polymerase (PARP) inhibitors. Quick determination of pathogenic variants is important to facilitate specific therapy in addition to the identification of familial predisposition to cancer.

Sign in / Sign up

Export Citation Format

Share Document